Potential roles of redox dysregulation in the development of schizophrenia
DO Perkins, CD Jeffries, KQ Do - Biological psychiatry, 2020 - Elsevier
Converging evidence implicates redox dysregulation as a pathological mechanism driving
the emergence of psychosis. Increased oxidative damage and decreased capacity of …
the emergence of psychosis. Increased oxidative damage and decreased capacity of …
[HTML][HTML] Mismatch negativity (MMN) as a tool for translational investigations into early psychosis: A review
M Tada, K Kirihara, S Mizutani, T Uka, N Kunii… - International Journal of …, 2019 - Elsevier
Mismatch negativity (MMN) reduction is one of the most robust findings among several
neurophysiological and neurocognitive measures in patients with schizophrenia. MMN is a …
neurophysiological and neurocognitive measures in patients with schizophrenia. MMN is a …
Mismatch negativity in response to auditory deviance and risk for future psychosis in youth at clinical high risk for psychosis
HK Hamilton, BJ Roach, PM Bachman, A Belger… - JAMA …, 2022 - jamanetwork.com
Importance Although clinical criteria for identifying youth at risk for psychosis have been
validated, they are not sufficiently accurate for predicting outcomes to inform major treatment …
validated, they are not sufficiently accurate for predicting outcomes to inform major treatment …
Functional connectivity signatures of NMDAR dysfunction in schizophrenia—integrating findings from imaging genetics and pharmaco-fMRI
AJ Gaebler, N Fakour, F Stöhr, J Zweerings… - Translational …, 2023 - nature.com
Both, pharmacological and genome-wide association studies suggest N-methyl-D-aspartate
receptor (NMDAR) dysfunction and excitatory/inhibitory (E/I)-imbalance as a major …
receptor (NMDAR) dysfunction and excitatory/inhibitory (E/I)-imbalance as a major …
Electroencephalography and event-related potential biomarkers in individuals at clinical high risk for psychosis
HK Hamilton, AK Boos, DH Mathalon - Biological psychiatry, 2020 - Elsevier
Clinical outcomes vary among youths at clinical high risk for psychosis (CHR-P), with
approximately 20% progressing to full-blown psychosis over 2 to 3 years and 30% achieving …
approximately 20% progressing to full-blown psychosis over 2 to 3 years and 30% achieving …
Clinical staging for youth mental disorders: Progress in reforming diagnosis and clinical care
PD McGorry, C Mei - Annual Review of Developmental …, 2021 - annualreviews.org
Current silo-based diagnostic systems for mental disorders lack utility and fail to fulfil a
fundamental purpose of diagnosis: to guide treatment planning and predict outcomes …
fundamental purpose of diagnosis: to guide treatment planning and predict outcomes …
Features of duration mismatch negativity around the onset of overt psychotic disorders: a longitudinal study
T Tateno, Y Higuchi, S Nakajima… - Cerebral …, 2021 - academic.oup.com
Reduced amplitude of duration mismatch negativity (dMMN) has been reported in psychotic
disorders and at-risk mental state (ARMS); however, few longitudinal MMN studies have …
disorders and at-risk mental state (ARMS); however, few longitudinal MMN studies have …
[HTML][HTML] Intact mismatch negativity responses in clinical high risk for psychosis and first-episode psychosis: Evidence from source-reconstructed event-related fields …
P Dheerendra, T Grent, R Gajwani, J Gross… - Biological Psychiatry …, 2024 - Elsevier
Background This study examined whether mismatch negativity (MMN) responses are
impaired in participants at clinical high risk for psychosis (CHR-P) and patients with first …
impaired in participants at clinical high risk for psychosis (CHR-P) and patients with first …
Mismatch negativity and clinical trajectories in psychotic disorders: Five-year stability and predictive utility
KR Donaldson, K Jonas, D Foti, EM Larsen… - Psychological …, 2023 - cambridge.org
BackgroundMismatch negativity (MMN) amplitude is reduced in psychotic disorders and
associated with symptoms and functioning. Due to these robust associations, it is often …
associated with symptoms and functioning. Due to these robust associations, it is often …
Staging model in psychiatry: Review of the evolution of electroencephalography abnormalities in major psychiatric disorders
S Lavoie, AR Polari, S Goldstone… - Early Intervention in …, 2019 - Wiley Online Library
Aim Clinical staging in psychiatry aims to classify patients according to the severity of their
symptoms, from stage 0 (increased risk, asymptomatic) to stage 4 (severe illness), enabling …
symptoms, from stage 0 (increased risk, asymptomatic) to stage 4 (severe illness), enabling …